BR112018068370A2 - composição farmacêutica em dose fixa contendo amlodipina, candesartan cilexetil e hidroclorotiazida para o tratamento de hipertensão - Google Patents

composição farmacêutica em dose fixa contendo amlodipina, candesartan cilexetil e hidroclorotiazida para o tratamento de hipertensão

Info

Publication number
BR112018068370A2
BR112018068370A2 BR112018068370A BR112018068370A BR112018068370A2 BR 112018068370 A2 BR112018068370 A2 BR 112018068370A2 BR 112018068370 A BR112018068370 A BR 112018068370A BR 112018068370 A BR112018068370 A BR 112018068370A BR 112018068370 A2 BR112018068370 A2 BR 112018068370A2
Authority
BR
Brazil
Prior art keywords
hydrochlorothiazide
hypertension
treatment
fixed dose
pharmaceutical composition
Prior art date
Application number
BR112018068370A
Other languages
English (en)
Inventor
Kahm Andreas
Jünemann Daniel
Original Assignee
Midas Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midas Pharma GmbH filed Critical Midas Pharma GmbH
Publication of BR112018068370A2 publication Critical patent/BR112018068370A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

a presente invenção refere-se a composições farmacêuticas com doses fixas contendo as substâncias ativas candesartan cilexetil, amlodipina e hidroclorotiazida para o tratamento de hipertensão.
BR112018068370A 2016-03-17 2017-03-16 composição farmacêutica em dose fixa contendo amlodipina, candesartan cilexetil e hidroclorotiazida para o tratamento de hipertensão BR112018068370A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16160794.0A EP3219309A1 (en) 2016-03-17 2016-03-17 Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
PCT/EP2017/056242 WO2017158094A1 (en) 2016-03-17 2017-03-16 Fixed dosed pharmaceutical composition comprising amiodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension.

Publications (1)

Publication Number Publication Date
BR112018068370A2 true BR112018068370A2 (pt) 2019-01-15

Family

ID=55542552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068370A BR112018068370A2 (pt) 2016-03-17 2017-03-16 composição farmacêutica em dose fixa contendo amlodipina, candesartan cilexetil e hidroclorotiazida para o tratamento de hipertensão

Country Status (5)

Country Link
US (1) US20200289523A1 (pt)
EP (2) EP3219309A1 (pt)
CN (1) CN109069432A (pt)
BR (1) BR112018068370A2 (pt)
WO (1) WO2017158094A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4052695A1 (en) * 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
CN113209035B (zh) * 2021-05-28 2022-07-08 海南锦瑞制药有限公司 苯磺酸左旋氨氯地平片及其制备方法
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3163645A (en) 1964-09-25 1964-12-29 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2-h-[1, 2, 4]-benzothiadiazine-1, 1-dioxides
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
ATE518526T1 (de) * 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
EP2106789A1 (en) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
DK2165702T3 (da) * 2008-09-17 2012-03-05 Helm Ag Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
CN102008480A (zh) * 2009-07-11 2011-04-13 邬林祥 一种治疗高血压含厄贝沙坦的复方制剂
CN101584700A (zh) * 2009-07-20 2009-11-25 王素云 一种药物组合物
CN102342942B (zh) * 2011-07-14 2016-08-31 海南锦瑞制药有限公司 一种全新口服固体药用组合物及其制备方法
PL236001B1 (pl) * 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję

Also Published As

Publication number Publication date
EP3429561A1 (en) 2019-01-23
US20200289523A1 (en) 2020-09-17
CN109069432A (zh) 2018-12-21
EP3219309A1 (en) 2017-09-20
WO2017158094A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
DOP2015000274A (es) Compuestos químicos
CR20150326A (es) Inhibidores de autotaxina
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
BR112017001968A2 (pt) embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
EA201690371A1 (ru) Пиридазиноновые соединения и их применение
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
PH12017501769A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112018068370A2 (pt) composição farmacêutica em dose fixa contendo amlodipina, candesartan cilexetil e hidroclorotiazida para o tratamento de hipertensão
EA201171414A1 (ru) Ингибиторы белков семейства iap
CL2017002229A1 (es) Inhibidores de bace1.
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.

B350 Update of information on the portal [chapter 15.35 patent gazette]